{
    "clinical_study": {
        "@rank": "109259", 
        "arm_group": {
            "arm_group_label": "EE20/DRSP/L-5-MTHF", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the red blood cell (RBC) and plasma concentrations\n      of folate in subjects treated with drospirenone (DRSP)/ethinyl estradiol (EE) plus\n      levomefolate calcium (L-5-MTHF) at 24 weeks with respect to basal determination.\n\n      Increased intake of folic acid (synthetic form of the naturally occurring B-vitamin) before\n      and in the first few weeks of pregnancy has been shown to reduce certain types of birth\n      defects.  This is important for women who may become pregnant following discontinuation of\n      oral contraception. Information about any side effects that may occur will also be\n      collected."
        }, 
        "brief_title": "Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Contraception", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, Mexican female subjects requesting contraception\n\n          -  Age >/=18 to </=45 years (inclusive); smokers must not be older than 30 years at the\n             time of informed consent\n\n          -  Normal or clinically insignificant cervical smear not requiring further follow-up; a\n             cervical smear has to be taken at the screening visit, or a normal result has to be\n             documented within the previous 6 months. Human papilloma virus (HPV) testing in\n             subjects with atypical squamous cells of undetermined significance (ASCUS) can be\n             used as an adjunctive test. Subjects with ASCUS can be included if they are negative\n             for high-risk HPV strains.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation (less than 6 months since delivery, abortion, or lactation\n             before start of treatment)\n\n          -  Body mass index (BMI) >30 kg/m2\n\n          -  Hypersensitivity to any ingredient in the study drug\n\n          -  Any diseases or conditions that can compromise the function of body systems and could\n             result in altered absorption, excessive accumulation, impaired metabolism, or altered\n             excretion of the study medication\n\n          -  Any diseases or conditions that might interfere with the conduct of the study or the\n             interpretation of the results\n\n          -  Any disease or condition that may worsen under hormonal treatment according to the\n             assessment and opinion of the investigator.\n\n          -  Undiagnosed abnormal genital bleeding\n\n          -  Abuse of alcohol, drugs or medicine (eg, laxatives)\n\n          -  Any medication that could result in excessive accumulation, impaired metabolism, or\n             altered excretion of the study drug"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902264", 
            "org_study_id": "16484"
        }, 
        "intervention": {
            "arm_group_label": "EE20/DRSP/L-5-MTHF", 
            "description": "One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks", 
            "intervention_name": "EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptives, Oral", 
                "Contraceptives, Oral, Combined", 
                "Estradiol", 
                "Ethinyl Estradiol", 
                "Drospirenone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Levomefolate calcium", 
            "Contraceptives, oral, combined", 
            "Neural tube defects"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Mexico, D.F.", 
                    "country": "Mexico", 
                    "state": "Distrito Federal", 
                    "zip": "CP 14050"
                }
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Open-label, Single-center Clinical Study to Investigate the Red Blood Cell and Plasma Folate Concentrations During a 24-week Treatment Period With the Combination of Drospirenone 3 mg Plus Ethinyl Estradiol 0.02 mg Plus Levomefolate Calcium 0.451 mg in Mexican Women Seeking Contraception", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Protection Against Health Risks", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in RBC folate concentration from baseline to Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change in plasma folate concentration from baseline to Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "RBC folate concentration", 
                "safety_issue": "No", 
                "time_frame": "Different time points up to 32 weeks"
            }, 
            {
                "measure": "Plasma folate concentration", 
                "safety_issue": "No", 
                "time_frame": "Different time points up to 32 weeks"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}